Apitoria Pharma Private Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is PANTOPRAZOLE SODIUM SESQUIHYDRATE USP, with a corresponding US DMF Number 19578.
Remarkably, this DMF maintains an Active status since its submission on June 28, 2006, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 23, 2013, and payment made on April 15, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II